Амитриптилин при синдроме раздражённой кишки
Перевод Г.Е. Заика (01.02.2023)
REFERENCES
1. Ford AC Sperber AD Corsetti M Camilleri M Irritable bowel syndrome.Lancet. 2020; 396: 1675-1688View in Article Scopus (328)PubMedSummaryFull TextFull Text PDFGoogle Scholar
2. Ford AC Forman D Bailey AG Axon ATR Moayyedi P Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior.Am J Gastroenterol. 2008; 103: 1229-1239View in Article Scopus (174)PubMed Crossref Google Scholar
3. Barberio B Houghton LA Yiannakou Y Savarino EV Black CJ Ford AC Symptom stability in Rome IV vs Rome III irritable bowel syndrome. Am J Gastroenterol. 2021; 116: 362-371 View in Article Scopus (32) PubMedCrossrefGoogle Scholar
4. Oka P Parr H Barberio B Black CJ Savarino EV Ford AC Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2020; 5: 908-917View in Article Scopus (317)PubMedSummaryFull TextFull Text PDFGoogle Scholar
5. Holtmann GJ Ford AC Talley NJ Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016; 1: 133-146 View in Article PubMedSummaryFull TextFull Text PDFGoogle Scholar
6. Vasant DH Paine PA Black CJ et al.British Society of Gastroenterology guidelines on the management of irritable bowel syndrome.Gut. 2021; 70: 1214-1240View in Article Scopus (191)PubMedCrossrefGoogle Scholar
7. Pace F Molteni P Bollani S et al. Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. Scand J Gastroenterol. 2003; 38: 1031-1038 View in Article Scopus (118)PubMed Crossref Google Scholar
8. Goodoory VC Guthrie EA Ng CE Black CJ Ford AC Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome.Aliment Pharmacol Ther. 2023; 57: 323-334View in Article Scopus (14) PubMed Crossref Google Scholar
9. Ballou S McMahon C Lee HN et al.Effects of irritable bowel syndrome on daily activities vary among subtypes based on results from the IBS in America survey. Clin Gastroenterol Hepatol. 2019; 17 (78.e3): 2471 View in Article PubMedSummary Full Text Full Text PDFGoogle Scholar
10. Goodoory VC Ng CE Black CJ Ford AC Impact of Rome IV irritable bowel syndrome on work and activities of daily living. Aliment Pharmacol Ther. 2022; 56: 844-856 View in Article Scopus (24)PubMedCrossrefGoogle Scholar
11. Goodoory VC Ng CE Black CJ Ford AC Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom. Aliment Pharmacol Ther. 2022; 56: 110-120 View in Article Scopus (29)PubMedCrossref Google Scholar
12. Zhang F Xiang W Li CY Li SC Economic burden of irritable bowel syndrome in China.World J Gastroenterol. 2016; 22: 10450-10460View in Article Scopus (48) PubMed Crossref Google Scholar
13. Peery AF Crockett SD Murphy CC et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2019; 156 (72.e11): 254View in Article PubMedSummaryFull TextFull Text PDFGoogle Scholar
14. Thompson WG Heaton KW Smyth GT Smyth C Irritable bowel syndrome: the view from general practice. Eur J Gastroenterol Hepatol. 1997; 9: 689-692 View in Article PubMed CrossrefGoogle Scholar
15. Hookway C Buckner S Crosland P Longson D Irritable bowel syndrome in adults in primary care: summary of updated NICE guidance.BMJ. 2015; 350: h701 View in Article Scopus (84)PubMedCrossrefGoogle Scholar
16. Black CJ Yuan Y Selinger CP et al.Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis.Lancet Gastroenterol Hepatol. 2020; 5: 117-131View in Article Scopus (97)PubMedSummaryFull TextFull Text PDFGoogle Scholar
17. Black CJ Staudacher HM Ford AC Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis.Gut. 2022; 71: 1117-1126 View in Article Scopus (113)PubMedCrossrefGoogle Scholar
18. Shivaji UN Ford AC Beliefs about management of irritable bowel syndrome in primary care: cross-sectional survey in one locality.Prim Health Care Res Dev. 2015; 16: 263-269View in Article Scopus (25)PubMedCrossrefGoogle Scholar
19. Everitt H McDermott L Leydon G Yules H Baldwin D Little P GP' management strategies for patients with insomnia: a survey and qualitative interview study.Br J Gen Pract. 2014; 64: e112-e119View in Article Scopus (83)PubMedCrossrefGoogle Scholar
20. Ruepert L Quartero AO de Wit NJ van der Heijden GJ Rubin G Muris JW Bulking agents, antispasmodics, and antidepressants for the treatment of irritable bowel syndrome.Cochrane Database Syst Rev. 2011; 2011CD003460 View in Article PubMed Google Scholar
21.Ford AC Lacy BE Harris LA Quigley EMM Moayyedi P Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis.Am J Gastroenterol. 2019; 114: 21-39View in Article Scopus (223) PubMed CrossrefGoogle Scholar
22. Sindrup SH Otto M Finnerup NB Jensen TS Antidepressants in the treatment of neuropathic pain.Basic Clin Pharmacol Toxicol. 2005; 96: 399-409View in Article Scopus (441)PubMedCrossrefGoogle Scholar
23. Saarto T Wiffen PJ Antidepressants for neuropathic pain.Cochrane Database Syst Rev. 2007; 4CD005454 View in Article Google Scholar
24. Wong J Motulsky A Abrahamowicz M Eguale T Buckeridge DL Tamblyn R Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system.BMJ. 2017; 356: j603View in Article Scopus (136)PubMedCrossrefGoogle Scholar
25. Gorard DA Libby GW Farthing MJ Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome.Aliment Pharmacol Ther. 1994; 8: 159-166View in Article PubMedCrossrefGoogle Scholar
26.Gorard DA Libby GW Farthing MJ Effect of a tricyclic antidepressant on small intestinal motility in health and diarrhea-predominant irritable bowel syndrome.Dig Dis Sci. 1995; 40: 86-95View in Article Scopus (118)PubMedCrossrefGoogle Scholar
27. Nigam P Kapoor KK Rastog CK Kumar A Gupta AK Different therapeutic regimens in irritable bowel syndrome.J Assoc Physicians India. 1984; 32: 1041-1044 View in Article PubMedGoogle Scholar
28. Vahedi H Merat S Momtahen S et al.Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome.Aliment Pharmacol Ther. 2008; 27: 678-684View in Article Scopus (119)PubMedCrossrefGoogle Scholar
29. Kaminski A Kamper A Thaler K Chapman A Gartlehner G Antidepressants for the treatment of abdominal pain-related functional gastrointestinal disorders in children and adolescents.Cochrane Database Syst Rev. 2011; 6CD008013 View in Article Google Scholar
30. Alderson SL Wright-Hughes A Ford AC et al.Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care.Trials. 2022; 23: 552View in Article Scopus (3)PubMedCrossrefGoogle Scholar
31. Mearin F Lacy BE Chang L et al.Bowel disorders.Gastroenterology. 2016; 150: 1393-1407View in Article Scopus (1844)SummaryFull TextFull Text PDFGoogle Scholar
32. Francis CY Morris J Whorwell PJ The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress.Aliment Pharmacol Ther. 1997; 11: 395-402View in Article PubMedCrossrefGoogle Scholar
33. NICE Suspected cancer: recognition and refer al. https://www.nice.org.uk/guidance/NG12/chapter/1-Recommendations-organised-by-site-of-cancer#lower-gastrointestinal-tract-cancersDate: 2015Date accessed: June 2, 2023View in Article Google Scholar
34. Heaton KW Ghosh S Braddon FE How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form.Gut. 1991; 32: 73-79View in Article Scopus (225)PubMed Crossref Google Scholar
35. Zigmond AS Snaith RP The hospital anxiety and depression scale.Acta Psychiatr Scand. 1983; 67: 361-370View in Article PubMedCrossrefGoogle Scholar
36. British Dietetic Association Irritable bowel syndrome and diet. https://www.bda.uk.com/resource/irritable-bowel-syndrome-diet.html Date accessed: June 2, 2023View in Article Google Scholar
37. Müller-Lissner S Koch G Talley NJ et al.Subject's Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials.J Clin Epidemiol. 2003; 56: 310-316View in Article Scopus (86)PubMedSummaryFull TextFull Text PDFGoogle Scholar
38. Patel P Bercik P Morgan DG et al.Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating.Aliment Pharmacol Ther. 2015; 41: 449-458View in Article Scopus (69) PubMed CrossrefGoogle Scholar
39. Spiller RC Humes DJ Campbell E et al.The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease.Aliment Pharmacol Ther. 2010; 32: 811-820View in Article Scopus (149)PubMedCrossrefGoogle Scholar
40. Mundt JC Marks IM Shear MK Greist JH The Work and Social Adjustment Scale: a simple measure of impairment in functioning.Br J Psychiatry. 2002; 180: 461-464View in Article Scopus (1683)PubMedCrossrefGoogle Scholar
41. Uher R Farmer A Henigsberg N et al.Adverse reactions to antidepressants. Br J Psychiatry. 2009; 195: 202-210View in Article Scopus (189)PubMedCrossrefGoogle Scholar
42. Everitt H Landau S Little P et al.Assessing Cognitive behavioural Therapy in Irritable Bowel (ACTIB): protocol for a randomised controlled trial of clinical-effectiveness and cost-effectiveness of therapist delivered cognitive behavioural therapy and web-based self-management in irritable bowel syndrome in adults.BMJ Open. 2015; 5e008622 View in Article Google Scholar
43. Everitt HA Landau S O'Reilly G et al. Assessing telephone-delivered cognitive-behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial. Gut. 2019; 68: 1613-1623 View in Article PubMed Google Scholar
44. Sisson G Ayis S Sherwood RA Bjarnason I Randomised clinical trial: a liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome–a 12 week double-blind study. Aliment Pharmacol Ther. 2014; 40: 51-62View in Article Scopus (94)PubMedCrossrefGoogle Scholar
45. Peckham EJ Relton C Raw J et al.Interim results of a randomised controlled trial of homeopathic treatment for irritable bowel syndrome. Homeopathy. 2014; 103: 172-177View in Article PubMedCrossrefGoogle Scholar
46.Rubin DB Inference and missing data.Biometrika. 1976; 63: 581-592View in Article Scopus (6548)CrossrefGoogle Scholar
47. European Medicines AgencyGuideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome.https://www.ema.europa.eu/en/evaluation-medicinal-products-treatment-irritable-bowel-syndrome-scientific-guidelineDate: 2014 Date accessed: June 2, 2023 View in Article Google Scholar
48. Loudon K Treweek S Sullivan F Donnan P Thorpe KE Zwarenstein M The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015; 350h2147 View in Article Scopus (1088)PubMedCrossrefGoogle Scholar
49. Food and Drug Administration Guidance for industry: irritable bowel syndrome–clinical evaluation of drugs for treatment. https://www.fda.gov/media/78622/download Date: 2012 Date accessed: June 2, 2023View in Article Google Scholar
50. Black CJ Yiannakou YHoughton LA Ford AC Epidemiological, clinical, and psychological characteristics of individuals with self-reported irritable bowel syndrome based on the Rome IV vs Rome III criteria.Clin Gastroenterol Hepatol. 2020; 18: 392-398.e2 View in Article Scopus (70)PubMedSummaryFull TextFull Text PDFGoogle Scholar
51. Everitt H Moss-Morris R Sibelli A et al.Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website.BMC Gastroenterol. 2013; 13: 68View in Article Scopus (55)PubMedCrossrefGoogle Scholar
52. Lembo A Kelley JM Nee J et al.Open-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial.Pain. 2021; 162: 2428-2435View in Article Scopus (49)PubMedCrossrefGoogle Scholar
53. Kaptchuk TJ Friedlander E Kelley JM et al.Placebos without deception: a randomized controlled trial in irritable bowel syndrome.PLoS One. 2010; 5e15591 View in ArticleScopus (675)CrossrefGoogle Scholar
54. Drossman DA Toner BB Whitehead WE et al.Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders.Gastroenterology. 2003; 125: 19-31View in Article Scopus (574)PubMed Summary Full TextFull Text PDFGoogle Scholar
55. Ford AC Moayyedi P Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome.Aliment Pharmacol Ther. 2010; 32: 144-158View in Article Scopus (172) PubMedCrossrefGoogle Scholar
56. Morgan V Pickens D Gautam S Kessler R Mertz H Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome.Gut. 2005; 54: 601-607View in Article Scopus (238)PubMedCrossrefGoogle Scholar
57. Zamani M Alizadeh-Tabari S Zamani V Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome.